TO THE EDITOR:

Continuous treatment with tyrosine kinase inhibitors (TKIs) induces a fast initial response and leads to long-term remission in most patients with chronic myeloid leukemia (CML). Consequently, the annual mortality in CML has decreased to 1% to 2%, and patients with CML approach the life expectancy of the general population. However, continuous treatment with TKI is costly and associated with significant side effects. Therefore, alternative treatment strategies are needed. Although TKI dose reductions during established molecular remission have only been considered recently,4,5  the potential of TKI treatment cessation for patients with CML in sustained molecular remission has been studied in greater detail.6,7  Several studies consistently report that ∼50% of patients with CML remain in treatment-free remission (TFR) for many years, whereas most of the other patients present with recurring disease levels after stopping TKI....

You do not currently have access to this content.